December 05, 2023
1 min watch
Save
VIDEO: Rogaratinib shows efficacy in gastrointestinal stromal tumor
Healio spoke with Sandra D’Angelo, MD, about a study of rogaratinib in patients with succinate dehydrogenase-deficient gastrointestinal stromal tumor presented at the Connective Tissue Oncology Society Annual Meeting.
“This is one of the first compounds that has shown to be efficacious in patients with [succinate dehydrogenase-deficient gastrointestinal stromal tumor]. Hopefully there will be more efforts with this particular pathway,” D’Angelo, research director of the sarcoma medical oncology service at Memorial Sloan Kettering Cancer Center, said in the interview.
Reference:
- Merriam P, et al. Paper 84. Presented at: Connective Tissue Oncology Society Annual Meeting; Nov. 1-4, 2023; Dublin.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
D’Angelo reports consulting/advising for Aadi Bioscience, Adaptimmune, Amgen, EMD Serono, GI Innovations, GSK, Immune Design, Immunocore, Incyte, Merck, Nektar, Pfizer, Rain Therapeutics and Servier; research funding from Amgen, Bristol Myers Squibb, Deciphera, EMD Serono, Incyte, Merck and Nektar; receiving travel/accommodations expenses from Adaptimmune, EMD Serono and Nektar; and being on a data safety monitoring board/advisory board for Adaptimmune, GSK, Merck and Nektar.